U.S. Markets open in 5 hrs 50 mins
  • S&P Futures

    4,606.50
    -48.25 (-1.04%)
     
  • Dow Futures

    35,550.00
    -246.00 (-0.69%)
     
  • Nasdaq Futures

    15,325.25
    -270.50 (-1.73%)
     
  • Russell 2000 Futures

    2,136.00
    -21.70 (-1.01%)
     
  • Crude Oil

    85.46
    +1.64 (+1.96%)
     
  • Gold

    1,814.00
    -2.50 (-0.14%)
     
  • Silver

    22.95
    +0.04 (+0.16%)
     
  • EUR/USD

    1.1403
    -0.0008 (-0.0684%)
     
  • 10-Yr Bond

    1.7720
    0.0000 (0.00%)
     
  • Vix

    21.44
    +1.13 (+5.56%)
     
  • GBP/USD

    1.3647
    0.0000 (-0.0000%)
     
  • USD/JPY

    114.7250
    +0.1450 (+0.1265%)
     
  • BTC-USD

    41,867.98
    -927.56 (-2.17%)
     
  • CMC Crypto 200

    1,003.06
    -22.67 (-2.21%)
     
  • FTSE 100

    7,562.96
    -48.27 (-0.63%)
     
  • Nikkei 225

    28,257.25
    -76.27 (-0.27%)
     

Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior to market open on Thursday, July 29, 2021. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 2919379. Archived webcasts will be available on Intercept’s website for approximately two weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

CONTACT

For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com

Media inquiries: media@interceptpharma.com

Source: Intercept Pharmaceuticals, Inc.